In mouse colitis models, FXR activation controlled IL17 expression in innate lymphoid cells (ILCs) and led to the expansion, differentiation and maturation of ILC precursor-like cells, proposing FXR as a potential therapeutic target also for patients. This evidence concerns the gene NR1H4 and colitis.